University Eye Hospital, Center for Ophthalmology, University of Tübingen, Tübingen, Baden-Württemberg, Germany.
Center for Rare Eye Diseases, University of Tübingen, Tübingen, Baden-Württemberg, Germany.
Br J Ophthalmol. 2022 Jun;106(6):831-838. doi: 10.1136/bjophthalmol-2020-318286. Epub 2021 Jan 20.
Voretigene neparvovec is a gene therapeutic agent for treatment of retinal dystrophies caused by bi-allelic mutations. In this study, we report on a novel and objective evaluation of a retinotopic photoreceptor rescue.
Seven eyes of five patients (14, 21, 23, 24, 36 years, 1 male, 4 females) with bi-allelic mutations have been treated with voretigene neparvovec. The clinical examinations included visual acuity testing, dark-adapted full-field stimulus threshold (FST), dark-adapted chromatic perimeter (DAC) with a 30-degree grid, and a 30 degrees grid scotopic and photopic chromatic pupil campimetry (CPC). All evaluations and spectral domain optical coherence tomography were performed at baseline, 1 month and 3 months.
All except the oldest patient had a measurable improvement of the rod function assessed via FST, DAC or scotopic CPC at 1 month. The visual acuity improved slightly or remained stable in all eyes. A cone function improvement as measured by photopic CPC was observed in three eyes. The gain of the dark-adapted threshold with blue FST and the DAC stimuli (cyan) average correlated strongly with age (R>0.7). The pupil response improvement in the scotopic CPC correlated with the baseline local retinal volume (R=0.5).
The presented protocols allow evaluating the individual spatial and temporal effects of gene therapy effects. Additionally, we explored parameters that correlated with the success of the therapy. CPC and DAC present new and fast ways to assess functional changes in retinotopic maps of rod and cone function, measuring complementary aspects of retinal function.
Voretigene neparvovec 是一种基因治疗药物,用于治疗由双等位基因突变引起的视网膜营养不良。在这项研究中,我们报告了一种新的、客观的视网膜定位光感受器挽救评估方法。
5 名患者(14、21、23、24、36 岁,1 名男性,4 名女性)的 7 只眼睛接受了 voretigene neparvovec 治疗。临床检查包括视力测试、暗适应全视野刺激阈值(FST)、暗适应色觉周边(DAC)30 度网格和 30 度网格暗适应和明适应色觉瞳孔Campimetry(CPC)。所有评估和频域光相干断层扫描均在基线、1 个月和 3 个月进行。
除最年长的患者外,所有患者的杆状功能均有可测量的改善,通过 FST、DAC 或暗适应 CPC 进行评估。所有眼睛的视力略有提高或保持稳定。三例患者观察到光适应 CPC 测量的锥状功能改善。暗适应阈值的增益与蓝色 FST 和 DAC 刺激(青色)的平均值与年龄呈强相关性(R>0.7)。暗适应 CPC 中瞳孔反应的改善与基线局部视网膜体积呈正相关(R=0.5)。
所提出的方案允许评估基因治疗效果的个体时空影响。此外,我们还探讨了与治疗成功相关的参数。CPC 和 DAC 提供了新的快速方法来评估杆状和锥状功能的视网膜定位图中的功能变化,测量视网膜功能的互补方面。